Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Hoechst Marion Roussel's Amaryl

Executive Summary

Hoechst Marion Roussel's Amaryl: Launch price for glimepiride is $22.60 AWP for 100 1 mg tablets, $36.75 for 2 mg and $69.10 for 4 mg. The company estimates that average cost for patients is 81 [cents] per day. Hoechst announced the availability of Amaryl April 1, following a Nov. 30 approval of the sulfonylurea agent for Type II diabetes ("The Pink Sheet" Dec. 4, 1995, T&G-1)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027958

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel